^
    Back
    Association details:
    Biomarker:FLT3 D835Y
    Cancer:Acute Myelogenous Leukemia
    Drug:Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

    Excerpt:
    ...Patients with a relevant FLT3-ITD mutation or D835Y point mutation 3....
    Trial ID:
    NCT00045942
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    EHA 2021
    Title:

    A CASE OF IDH1 MUTATED AML IN AN ADULT PATIENT AFFECTED BY OLLIER DISEASE, BIOLOGICAL SPECULATIONS AND CLINICAL IMPLICATIONS

    Published date:
    05/12/2021
    Excerpt:
    ...a 35 years old man was admitted to our unit with haemorrhagic symptoms….A bone marrow evaluation led to a diagnosis of AML, FAB M2, with normal karyotype, NPM1 exon 11 (W288Cfs*12), FLT3 TKD (D835Y and I836del) and IDH1 (R132H) mutation. An induction chemotherapy with “7+3” associated with midostaurin (days 8-21) was administered and complete remission was obtained.
    Secondary therapy:
    7+3 (DAC)